The year started well for CZM with revenue growing 9% (at CER) in Q1, led by robust growth momentum in Ophthalmology and Microsurgery. Geographically, APAC and EMEA reported double-digit growth, while the Americas traded in the red. While operating profit surged 23.1%, due to temporarily reduced R&D expenses, higher financial and tax expenses meant that the EPS was flat yoy. Given CZM’s robust product portfolio, the company remains on track to meet its revenue and profitability targ ....